
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Nyrada is a biotechnology business based in Australia. Nyrada shares (NYR) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Nyrada has a trailing 12-month revenue of around $2.3 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Nyrada
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Nyrada. Find the share by name or ticker symbol: NYR. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Nyrada reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Nyrada. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
Our top pick for
US stocks

Our top pick for
Overall broker

Our top pick for
Low-cost broker

Nyrada stock price (ASX:NYR)
Use our graph to track the performance of NYR stocks over time.Nyrada shares at a glance
52-week range | $0.13 - $0.365 |
---|---|
50-day moving average | $0.1657 |
200-day moving average | $0.211 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.026 |
Compare share trading platforms
Is it a good time to buy Nyrada stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Nyrada price performance over time
Historical closes compared with the last close of A$0.15
1 week (2022-06-24) | 11.11% |
---|---|
1 month (2022-06-02) | -3.23% |
3 months (2022-04-01) | -26.83% |
6 months (2021-12-31) | -37.50% |
1 year (2021-07-02) | -56.52% |
---|---|
2 years (2020-07-02) | -14.29% |
Nyrada financials
Revenue TTM | $2.3 million |
---|---|
Gross profit TTM | $160,972 |
Return on assets TTM | -27.06% |
Return on equity TTM | -46.75% |
Profit margin | -159.53% |
Book value | 0.078 |
Market capitalisation | $23.4 million |
TTM: trailing 12 months
Nyrada share dividends
We're not expecting Nyrada to pay a dividend over the next 12 months.
Nyrada share price volatility
Over the last 12 months, Nyrada's shares have ranged in value from as little as $0.13 up to $0.365. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Nyrada's is 1.4937. This would suggest that Nyrada's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Nyrada overview
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in the drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; NYR-BI01, a neuroprotectant drug, to reduce the disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company has collaboration with Walter Reed Army Institute of Research and University of New South Wales, Sydney for advancement of preclinical neuroprotection compound for traumatic brain injury. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.
Stocks similar to Nyrada
Nyrada in the news
Frequently asked questions
More guides on Finder
-
How to invest in the Australia Sunny Glass Group IPO
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
-
How to buy Kincora Copper (KCC) shares
Steps to owning and managing Kincora Copper shares.
-
How to invest in the Dragon Mountain Gold IPO
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
-
How to buy Arcadia Minerals (AM7) shares
Steps to owning and managing Arcadia Minerals shares.
-
How to buy Nexgen Energy (NXG) shares
Steps to owning and managing Nexgen Energy shares.
-
How to buy Keypath Education (KED) shares
Steps to owning and managing Keypath Education shares.
-
What are green bonds and how do they impact the world?
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
-
5 best ways to invest money in Australia in 2022
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
-
How to buy EBR Systems (EBR) shares
Steps to owning and managing EBR Systems shares.
-
How to buy 5E Advanced Materials (5EA) shares
Steps to owning and managing 5E Advanced Materials shares.
Ask an Expert